Blood test for colon cancer screening beneficial for some seniors, but not for many others

May 9, 2011

A new study of U.S. veterans ages 70 and older finds that the healthiest get the most benefit from current colon cancer screening methods. However, for many less healthy veterans the burdens of screening may outweigh the benefits.

"This study shows that we really need to target screening in older adults, so that those who will benefit do get screened and followed-up while those who won't benefit aren't exposed to unnecessary burdens," said Christine E. Kistler, MD, assistant professor of Family Medicine at the University of North Carolina at Chapel Hill and lead author of the study.

The study was published online on May 9, 2011, by the journal . Kistler led the study while completing a geriatrics fellowship at the University of California, San Francisco and the San Francisco Veterans Affairs Medical Center. She has since joined the faculty at the UNC School of Medicine.

In the study, 212 patients ages 70 and older who were treated at four Veterans Affairs medical facilities were followed for 7 years after receiving a positive result in a fecal occult blood test (FOBT). The test, which determines whether or not occult (hidden) blood is present in the stool, is the most common method used in the VA health system as an initial screen for colon cancer. A follow-up colonoscopy within one year is recommended for patients with a positive FOBT.

The study found that a little more than half of the patients received a follow-up colonoscopy. Among those who did, more than 25 percent were found to have significant disease such as precancerous adenomas or cancer, were treated, and survived for more than five years. However, 59 percent of those who received follow-up colonoscopy did not have cancer, 16 percent died of other causes within 5 years, and 10 percent suffered complications from either colonoscopy or cancer treatment.

Among those who did not receive follow-up colonoscopy, nearly half died of other causes within five years of their positive FOBT. Four patients ultimately died of colon cancer -- three within the first 5 years of their positive FOBT.

Of the 212 patients in the study, the researchers defined 33 patients, a little more than 15 percent, as receiving a net benefit from their positive FOBT. Another 30 patients, about 14 percent, were defined as receiving indeterminate benefit. The remaining 149 patients, about 70 percent, were defined as receiving a net burden from colorectal .

Kistler said there was "a spectrum of burden" among those in the net burden group. For some the burden was that they never received a follow-up colonoscopy. Others received a but it found no evidence of cancer, and some died of causes other than colon cancer. In each of these examples, the received no benefit as a result of their positive FOBT, Kistler said.

"This study shows that we need to do a better job of targeting screening to those seniors who are healthy and functional and are likely to benefit. At the same time, this study also shows that we need to seriously examine why those seniors who are not likely to benefit are being subjected to ," Kistler said.

Related Stories

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.